Horizon Biotechnology Fund

ISIN
LU1897414303

NAV
USD 16.40
As of 2020/10/21

1-Day Change
USD -0.07 (-0.43%)
As of 2020/10/21

Key investment risks:
• The Fund invests at least 80% in equities or equity-related instruments of biotechnology and biotechnology-related companies worldwide.
• Investments involve varying degree of investment risks (e.g. liquidity, market, economic, political, regulatory, taxation, financial, interest rate, hedging and currency risks). In extreme market conditions,

More

you may lose your entire investment.
• Investments in financial derivatives instruments (“FDIs”) (such as futures, swaps, options, forwards, equity swaps) involve specific risks (e.g. counterparty, liquidity, leverage, volatility, valuation risk and over-the-counter transaction risk). The Fund may use FDIs with the aim of making investment gains (up to 10% of its net assets), to reduce risk and to manage the Fund more efficiently.
• The Fund's investments are concentrated in biotechnology or biotechnology-related industry and may subject to higher industry risk.
• The Fund may at times invest a large portion of its assets in certain geographical area(s) and may subject to higher concentration risk.
• The investment decision is yours. If you are in any doubt about the contents of this document, you should seek independent professional financial advice.
• Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Less

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

Less

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, PhD, CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Discrete Performance (%)
As of 2020/09/30
A2 USD
 
Quarter End
As of 2020/09/30
Sep-2019 - Sep-2020 Sep-2018 - Sep-2019 Sep-2017 - Sep-2018 Sep-2016 - Sep-2017 Sep-2015 - Sep-2016
58.03% - - - -
Cumulative Performance (%)
As of 2020/09/30
A2 USD (Net)
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2018/12/10
A2 USD 2.54% 6.64% 45.34% 26.32% 58.03% - - 57.40%
ANNUAL FEES & EXPENSES (As of Fiscal Year End, 2019/12/31)
Initial Charge 5.00%
Annual Charge 1.20%
Ongoing Charge
(As of 2019/12/31)
2.11%
Performance Fee 20% of the 'Relevant Amount'

Portfolio

Top Holdings (As of 2020/09/30)
% of Fund
Ascendis Pharma 3.68
Sarepta Therapeutics 3.36
FORMA Therapeutics 2.86
Neurocrine Biosciences 2.69
Horizon Therapeutics 2.55
Cardiff Oncology 2.33
Akero Therapeutics 2.31
BioMarin Pharmaceutical 2.23
Essa Pharma 2.23
Alexion Pharmaceuticals 2.19

Documents

TOP